Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189433 | 0.80 | TYMP (0.53) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL2745392 | 0.80 | TYMP (0.45) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL28562422 | 0.76 | TYMP (0.46) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL16632478 | 0.74 | TYMP (0.43) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL3015728 | 0.72 | TYMP (0.54) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL11631449 | 0.72 | KMT2A (0.55) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL14491 | 0.70 | TYMP (0.49) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL11792243 | 0.69 | P2RX4 (0.59) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL31621004 | 0.69 | TYMP (0.60) | TYMPKMT2AP2RX4IDO1NPC1 | |
| SCHEMBL2892389 | 0.68 | TYMP (0.43) | TYMPKMT2AP2RX4IDO1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598923-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | UNIV HONG KONG CHINESE (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20170218001-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-08-03 | — | — | US | disclosed |
| US-20170218001-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2017-08-03 | — | — | US | disclosed |
| WO-2015177351-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | UNIVERSITY COLLEGE CORK (IE) | 2015-11-26 | — | — | WO | disclosed |
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1828145-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY | 2006-10-05 | — | — | US | disclosed |
| WO-2006063281-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-0265506-A1 | A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER | FARMACEUTISK LABORATORIUM FERRING A/S (DK) | 1988-05-04 | — | — | EP | disclosed |
| WO-1987006581-A1 | A PRODRUG FORM OF 5-FLUOROURACIL AND A METHOD OF TREATMENT OF CANCER | FARMACEUTISK LABORATORIUM FERRING A/S (DK) | 1987-11-05 | — | — | WO | disclosed |
| EP-0062068-B1 | N-PHTHALIDYL-5-FLUOROURACIL DERIVATIVES | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1985-06-12 | — | — | EP | disclosed |
| US-4481203-A | ANTICANCER AGENTS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1984-11-06 | — | — | US | disclosed |
| EP-0062068-A1 | N-PHTHALIDYL-5-FLUOROURACIL DERIVATIVES | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1982-10-13 | — | — | EP | disclosed |
| US-4088646-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | TYMP 739/4885KMT2A 4123/4885P2RX4 3587/4885 |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | HAVCR2, PNP, DCTD | TYMP 6/4885KMT2A 4065/4885P2RX4 2205/4885 |
| US-20230357168-A1 | CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION | PNP, SLC29A1, SLC29A2 | TYMP 17/4885KMT2A 2720/4885P2RX4 684/4885 |
| US-20170218001-A1 | PHOSPHONATE NUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISEASES | NR3C1, NR2E3, NR2E1 | TYMP 362/4885KMT2A 1571/4885P2RX4 456/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | TYMP 2654/4885KMT2A 4760/4885P2RX4 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.